232 related articles for article (PubMed ID: 16344269)
1. Efficacy of new retinoids in the prevention of mammary cancers and correlations with short-term biomarkers.
Grubbs CJ; Lubet RA; Atigadda VR; Christov K; Deshpande AM; Tirmal V; Xia G; Bland KI; Eto I; Brouillette WJ; Muccio DD
Carcinogenesis; 2006 Jun; 27(6):1232-9. PubMed ID: 16344269
[TBL] [Abstract][Full Text] [Related]
2. Short-term modulation of cell proliferation and apoptosis and preventive/therapeutic efficacy of various agents in a mammary cancer model.
Christov K; Grubbs CJ; Shilkaitis A; Juliana MM; Lubet RA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5488-96. PubMed ID: 17875779
[TBL] [Abstract][Full Text] [Related]
3. Conformationally defined 6-s-trans-retinoic acid analogs. 3. Structure-activity relationships for nuclear receptor binding, transcriptional activity, and cancer chemopreventive activity.
Muccio DD; Brouillette WJ; Alam M; Vaezi MF; Sani BP; Venepally P; Reddy L; Li E; Norris AW; Simpson-Herren L; Hill DL
J Med Chem; 1996 Sep; 39(19):3625-35. PubMed ID: 8809153
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Targretin on methylnitrosourea-induced mammary cancers: prevention and therapy dose-response curves and effects on proliferation and apoptosis.
Lubet RA; Christov K; Nunez NP; Hursting SD; Steele VE; Juliana MM; Eto I; Grubbs CJ
Carcinogenesis; 2005 Feb; 26(2):441-8. PubMed ID: 15591091
[TBL] [Abstract][Full Text] [Related]
5. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
6. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
7. Modulation of methylnitrosourea-induced breast cancer in Sprague Dawley rats by dehydroepiandrosterone: dose-dependent inhibition, effects of limited exposure, effects on peroxisomal enzymes, and lack of effects on levels of Ha-Ras mutations.
Lubet RA; Gordon GB; Prough RA; Lei XD; You M; Wang Y; Grubbs CJ; Steele VE; Kelloff GJ; Thomas CF; Moon RD
Cancer Res; 1998 Mar; 58(5):921-6. PubMed ID: 9500451
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers.
Lubet RA; Clapper ML; McCormick DL; Pereira MA; Chang WC; Steele VE; Fischer SM; Juliana MM; Grubbs CJ
Oncol Rep; 2012 May; 27(5):1400-6. PubMed ID: 22307264
[TBL] [Abstract][Full Text] [Related]
9. Retinoids as chemopreventive agents for breast cancer.
Moon RC; Mehta RG; Detrisac CJ
Cancer Detect Prev; 1992; 16(1):73-9. PubMed ID: 1551141
[TBL] [Abstract][Full Text] [Related]
10. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.
Gottardis MM; Bischoff ED; Shirley MA; Wagoner MA; Lamph WW; Heyman RA
Cancer Res; 1996 Dec; 56(24):5566-70. PubMed ID: 8971154
[TBL] [Abstract][Full Text] [Related]
11. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene).
Vedell PT; Lu Y; Grubbs CJ; Yin Y; Jiang H; Bland KI; Muccio DD; Cvetkovic D; You M; Lubet R
Mol Pharmacol; 2013 Mar; 83(3):698-708. PubMed ID: 23292798
[TBL] [Abstract][Full Text] [Related]
12. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.
Bischoff ED; Gottardis MM; Moon TE; Heyman RA; Lamph WW
Cancer Res; 1998 Feb; 58(3):479-84. PubMed ID: 9458093
[TBL] [Abstract][Full Text] [Related]
13. Estradiol and progesterone can prevent rat mammary cancer when administered concomitantly with carcinogen but do not modify surviving tumor histology, estrogen receptor alpha status or Ha-ras mutation frequency.
Swanson SM; Christov K
Anticancer Res; 2003; 23(4):3207-13. PubMed ID: 12931682
[TBL] [Abstract][Full Text] [Related]
14. Topical delivery of 13-cis-retinoic acid by inhalation up-regulates expression of rodent lung but not liver retinoic acid receptors.
Wang DL; Marko M; Dahl AR; Engelke KS; Placke ME; Imondi AR; Mulshine JL; De Luca LM
Clin Cancer Res; 2000 Sep; 6(9):3636-45. PubMed ID: 10999756
[TBL] [Abstract][Full Text] [Related]
15. Prevention of methylnitrosourea-induced mammary cancers by 9-cis-retinoic acid and/or vitamin D3.
Cope MB; Steele VE; Eto I; Juliana MM; Hill DL; Grubbs CJ
Oncol Rep; 2002; 9(3):533-7. PubMed ID: 11956623
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.
Gamage SD; Bischoff ED; Burroughs KD; Lamph WW; Gottardis MM; Walker CL; Fuchs-Young R
J Pharmacol Exp Ther; 2000 Nov; 295(2):677-81. PubMed ID: 11046105
[TBL] [Abstract][Full Text] [Related]
17. Correlation of chemopreventive efficacy data from the human epidermal cell assay with in vivo data.
Elmore E; Luc TT; Li HR; Buckmeier JA; Steele VE; Kelloff GJ; Redpath JL
Anticancer Res; 2000; 20(1A):27-32. PubMed ID: 10769631
[TBL] [Abstract][Full Text] [Related]
18. Src is a novel potential off-target of RXR agonists, 9-cis-UAB30 and Targretin, in human breast cancer cells.
Kim MS; Lim DY; Kim JE; Chen H; Lubet RA; Dong Z; Bode AM
Mol Carcinog; 2015 Dec; 54(12):1596-604. PubMed ID: 25328014
[TBL] [Abstract][Full Text] [Related]
19. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
[TBL] [Abstract][Full Text] [Related]
20. Retinoids as cancer-preventive agents.
Sankaranarayanan R; Mathew B
IARC Sci Publ; 1996; (139):47-59. PubMed ID: 8923019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
